Cargando…
Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo
BACKGROUND: Malignant mesothelioma (MM) is a rare tumor with a dismal prognosis. The low efficacy of current treatment options highlights the urge to identify more effective therapies aimed at improving MM patients’ survival. Bortezomib (Bor) is a specific and reversible inhibitor of the chymotrypsi...
Autores principales: | Benvenuto, Monica, Angiolini, Valentina, Focaccetti, Chiara, Nardozi, Daniela, Palumbo, Camilla, Carrano, Raffaele, Rufini, Alessandra, Bei, Riccardo, Miele, Martino Tony, Mancini, Patrizia, Barillari, Giovanni, Cirone, Mara, Ferretti, Elisabetta, Tundo, Grazia Raffaella, Mutti, Luciano, Masuelli, Laura, Bei, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111665/ https://www.ncbi.nlm.nih.gov/pubmed/37069690 http://dx.doi.org/10.1186/s13062-023-00374-w |
Ejemplares similares
-
Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma
por: Palumbo, Camilla, et al.
Publicado: (2023) -
Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo
por: Bei, Roberto, et al.
Publicado: (2022) -
Tumor Microenvironment Remodeling in Gastrointestinal Cancer: Role of miRNAs as Biomarkers of Tumor Invasion
por: Lucarini, Valeria, et al.
Publicado: (2023) -
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
por: Benvenuto, Monica, et al.
Publicado: (2021) -
DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
por: Cifaldi, Loredana, et al.
Publicado: (2023)